公开(公告)号：MX2022001204A

公开(公告)日：2022-05-03

申请号：MX2022001204

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  SUGATA KENJI ,  NAKATSUGAWA MUNEHIDE ,  YAMASHITA YUKI ,  RAHMAN MUHAMMED AASHIQ

IPC: G01N33/566 ,  C07K14/73 ,  C12N15/12

Abstract: La presente descripción hace referencia a métodos de identificación de receptores de linfocitos T (TCR) específicos de MHC de clase II. En determinados aspectos, el método comprende poner un linfocito T en contacto con un complejo que comprende (i) una molécula de MHC de clase II que tiene una mayor afinidad por CD4 que las moléculas de MHC de clase II de origen natural y (ii) un péptido, por ejemplo, un epítopo. En determinados aspectos, la molécula de HLA de clase II comprende una cadena beta que tiene una o más mutaciones con respecto a una secuencia de cadena beta de tipo salvaje.

公开(公告)号：CA3146307A1

公开(公告)日：2021-02-04

申请号：CA3146307

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  NAKATSUGAWA MUNEHIDE ,  YAMASHITA YUKI ,  RAHMAN MUHAMMED AASHIQ ,  GUO TINGXI

IPC: C07K14/74

Abstract: The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DP beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 112 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 141 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

公开(公告)号：CA3146290A1

公开(公告)日：2021-02-04

申请号：CA3146290

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  NAKATSUGAWA MUNEHIDE ,  YAMASHITA YUKI ,  SUGATA KENJI ,  RAHMAN MUHAMMED AASHIQ

IPC: G01N33/566 ,  C07K14/73 ,  C12N15/12

Abstract: The present disclosure is directed to methods of identifying MHC class II-specific T cell receptors (TCRs). In certain aspects, the method comprises contacting a T cell with a complex comprising an (i) MHC class II molecule having a higher affinity for CD4 than naturally occurring MHC class II molecules and (ii) a peptide, e.g., an epitope. In certain aspects, the HLA class II molecule comprises a beta chain having one or more mutations relative to a wild-type beta chain sequence.

公开(公告)号：AU2020323767A1

公开(公告)日：2022-03-03

申请号：AU2020323767

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  NAKATSUGAWA MUNEHIDE ,  YAMASHITA YUKI ,  RAHMAN MUHAMMED AASHIQ ,  GUO TINGXI

IPC: C07K14/74 ,  A61P31/00 ,  A61P35/00 ,  C12N5/10 ,  C12N15/12 ,  C12Q1/02 ,  G01N33/566

Abstract: The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DP beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 112 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 141 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

公开(公告)号：AU2020321710A1

公开(公告)日：2022-03-03

申请号：AU2020321710

申请日：2020-07-29

Applicant: UNIV HEALTH NETWORK

Inventor： HIRANO NAOTO ,  NAKATSUGAWA MUNEHIDE ,  YAMASHITA YUKI ,  SUGATA KENJI ,  RAHMAN MUHAMMED AASHIQ

IPC: G01N33/566 ,  C07K14/73 ,  C12N15/12

Abstract: The present disclosure is directed to methods of identifying MHC class II-specific T cell receptors (TCRs). In certain aspects, the method comprises contacting a T cell with a complex comprising an (i) MHC class II molecule having a higher affinity for CD4 than naturally occurring MHC class II molecules and (ii) a peptide, e.g., an epitope. In certain aspects, the HLA class II molecule comprises a beta chain having one or more mutations relative to a wild-type beta chain sequence.

公开(公告)号：CA3022227A1

公开(公告)日：2017-11-02

申请号：CA3022227

申请日：2017-04-27

Applicant: UNIV HEALTH NETWORK UHN

Inventor： HIRANO NAOTO ,  NAKATSUGAWA MUNEHIDE ,  RAHMAN MUHAMMED AASHIQ ,  MURATA KENJI

IPC: C07K14/74 ,  C12N5/10 ,  C12N15/12 ,  G01N33/53 ,  G01N33/569

Abstract: There is provided herein, the use of mammalian derived HLA class I molecule for in vitro peptide exchange. For example, there is provided a method of producing an HLA class I molecule complexed to a pre-selected peptide comprising: (a) providing a mammalian derived HLA class 1 molecule complexed to an existing peptide; (b) incubating, in vitro, the HLA class I molecule complexed to the existing peptide with the pre-selected peptide, wherein the pre-selected peptide is at a concentration sufficient to replace the existing peptide to produce the HLA class I molecule complexed to the pre-selected peptide; and the HLA class I molecule comprises a1, a1, a2, a3 and ß2m domains.